Immunogenicity of BNT162b2 vaccine booster against SARS-CoV-2 Delta and Omicron variants in nursing home residents: A prospective observational study in older adults aged from 68 to 98 years.
BNT162b2 vaccine
Boost
Delta
Older people
Omicron
SARS-CoV-2
immunogenicity
Journal
The Lancet regional health. Europe
ISSN: 2666-7762
Titre abrégé: Lancet Reg Health Eur
Pays: England
ID NLM: 101777707
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
entrez:
26
4
2022
pubmed:
27
4
2022
medline:
27
4
2022
Statut:
ppublish
Résumé
The present study aimed to evaluate the persistent immunogenicity offered by a third dose of BNT162b2 against Delta and Omicron variants, in nursing home (NH) residents. In this monocenter prospective observational study, anti-spike IgG levels, S1 domain reactive T cell counts, serum neutralizing antibody titers against Delta and Omicron variants were compared before and up to three months after the BNT162b2 booster dose, in NH residents without COVID-19 (COVID-19 naive) or with COVID-19 prior to initial vaccination (COVID-19 recovered). 106 NH residents (median [interquartile range] age: 86·5 [81;91] years) were included. The booster dose induced a high increase of anti-spike antibody levels in all subjects ( The booster dose restores high neutralization titers against Delta in all NH residents, and at a lower level against Omicron in a large majority of participants. Future studies are warranted to assess if repeated BNT162b2 booster doses or new specific vaccines might be considered for protecting such fragile patients against Omicron and/or future SARS-CoV-2 variants. French government through the Programme Investissement d'Avenir (I-SITE ULNE/ANR-16-IDEX-0004 ULNE) and the Label of COVID-19 National Research Priority (National Steering Committee on Therapeutic Trials and Other COVID-19 Research, CAPNET).
Sections du résumé
Background
UNASSIGNED
The present study aimed to evaluate the persistent immunogenicity offered by a third dose of BNT162b2 against Delta and Omicron variants, in nursing home (NH) residents.
Methods
UNASSIGNED
In this monocenter prospective observational study, anti-spike IgG levels, S1 domain reactive T cell counts, serum neutralizing antibody titers against Delta and Omicron variants were compared before and up to three months after the BNT162b2 booster dose, in NH residents without COVID-19 (COVID-19 naive) or with COVID-19 prior to initial vaccination (COVID-19 recovered).
Findings
UNASSIGNED
106 NH residents (median [interquartile range] age: 86·5 [81;91] years) were included. The booster dose induced a high increase of anti-spike antibody levels in all subjects (
Interpretation
UNASSIGNED
The booster dose restores high neutralization titers against Delta in all NH residents, and at a lower level against Omicron in a large majority of participants. Future studies are warranted to assess if repeated BNT162b2 booster doses or new specific vaccines might be considered for protecting such fragile patients against Omicron and/or future SARS-CoV-2 variants.
Funding
UNASSIGNED
French government through the Programme Investissement d'Avenir (I-SITE ULNE/ANR-16-IDEX-0004 ULNE) and the Label of COVID-19 National Research Priority (National Steering Committee on Therapeutic Trials and Other COVID-19 Research, CAPNET).
Identifiants
pubmed: 35469147
doi: 10.1016/j.lanepe.2022.100385
pii: S2666-7762(22)00078-3
pmc: PMC9022478
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100385Informations de copyright
© 2022 The Authors.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nat Med. 2021 Nov;27(11):2032-2040
pubmed: 34588689
Am J Clin Nutr. 2005 Oct;82(4):777-83
pubmed: 16210706
Euro Surveill. 2022 Mar;27(9):
pubmed: 35241215
Euro Surveill. 2021 Dec;26(50):
pubmed: 34915977
Emerg Infect Dis. 2022 Feb;28(2):460-462
pubmed: 34860154
Biomed Res Int. 2020 Nov 4;2020:8870249
pubmed: 33204723
Clin Infect Dis. 2021 Dec 6;73(11):2112-2115
pubmed: 33993265
Cell Rep Med. 2022 Jan 24;3(2):100529
pubmed: 35233550
Lancet Microbe. 2022 Jan;3(1):e52-e61
pubmed: 34806056
Front Immunol. 2021 Nov 16;12:778679
pubmed: 34868051
J Med Virol. 2022 Apr;94(4):1728-1733
pubmed: 34897752
CMAJ. 2005 Aug 30;173(5):489-95
pubmed: 16129869
Nature. 2022 Mar;603(7902):679-686
pubmed: 35042229
J Infect Dis. 2022 Jun 1;225(11):1909-1914
pubmed: 34979030
Nature. 2022 Feb;602(7898):671-675
pubmed: 35016199
Nature. 2022 Feb;602(7898):654-656
pubmed: 35016196
Nature. 2022 Feb;602(7898):682-688
pubmed: 35016197
Clin Transl Immunology. 2020 Dec 23;9(12):e1217
pubmed: 33376594
Cell. 2022 Feb 3;185(3):457-466.e4
pubmed: 34995482
Cell Discov. 2022 Jan 17;8(1):4
pubmed: 35034952
J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56
pubmed: 11253156
Emerg Microbes Infect. 2022 Dec;11(1):337-343
pubmed: 34935594